Authors: Martha Powell, Future Science Group
Remember to visit us at booth 4823, or follow our Twitter updates @IDHubFSG!
Pick of the Posters
- Characterization of a pan-resistant Pseudomonas aeruginosa containing blaNDM-1 and blaIMP-1 from David R. Lonsway (CDC, GA, USA) reports on a highly antibiotic-resistant P. aeruginosa cultured in September 2018 from a urine specimen collected from a 63-year-old male concluding that newer drugs/drug combinations such as plazomicin and aztreonam-avibactam showed limited activity in vitro against this pan-resistant P. aeruginosa harboring two MBL genes. The Texas healthcare facilities, where the patient was hospitalized, implemented prospective surveillance as part of the CDC containment strategy and have continued to monitor for both carbapenem-resistant Enterobacteriaceae and P. aeruginosa.
- Construction and characterization of multimodal Th17 stimulating Pseudomonas aeruginosa vaccines by Christina Merakou (Boston Children’s Hospital, MA, USA) describes a new vaccine approach bringing together antibodies and Th17 cells. In the current studies, the team tested whether mixing PopB/PcrH, a secretion system protein, with OprF/I, a P. aeruginosa outer membrane fusion protein known to elicit protective antibodies and Th1 responses, would enhance protective efficacy, reporting that combining a Th17 vaccine antigen (PopB) with antigens that elicit functional antibodies (OprF/I) will lead to a broadly and potently protective vaccine against P. aeruginosa infections.
Best of social media
— Hedieh Attai (@Hedieh_Attai) June 22, 2019
— Rich Davis 🦠🔬🧫 (@richdavisphd) June 22, 2019
Chloramphenicol is really a great example of academic and industry collaboration but I had never heard it was first isolated from soil in Venezuela and in Illinois at nearly the same time – credit went to who published first – timing is always important #ASMicrobe pic.twitter.com/Fjk7gK3YPr
— Larry Lynam (@scopedbylarry) June 22, 2019